Using MRI to improve cancer radiotherapy
Northern Alberta Linac-MR Image-Guided Human Clinical Trials - 1
This study is testing if using special MRI scans can help doctors see tumors better during radiation treatment for adults with cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AHS Cancer Control Alberta Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT04358913 on ClinicalTrials.gov |
What this trial studies
This pilot phase clinical trial aims to optimize magnetic resonance imaging (MRI) sequences using the Alberta linac-MR P3 system for adult cancer patients undergoing high dose external beam radiotherapy. Participants will undergo a single MR imaging session lasting 30 to 40 minutes, with the potential for an optional sub-study involving five additional sessions to assess inter-fraction motion. The goal is to develop high-quality MR images that can enhance the visualization of tumors during treatment, ultimately improving patient outcomes in radiotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are fit for high dose external beam radiation therapy.
Not a fit: Patients with contraindications for MRI or those unable to lie flat and still during the scan may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate targeting of tumors during radiotherapy, potentially improving treatment effectiveness and reducing side effects.
How similar studies have performed: While the use of MRI in radiotherapy is an emerging field, similar studies have shown promise in improving treatment accuracy and patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥ 18 years of age * Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist Exclusion Criteria: * Patients with contraindications for MRI * Patients who are unable to lie flat and still for the duration of the expected scan acquisition * Patients who are unable to provide informed consent
Where this trial is running
Edmonton, Alberta
- Cross Cancer Institute — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Nawaid Usmani, MD — Cross Cancer Institute, Alberta Health Services
- Study coordinator: Nawaid Usmani, MD
- Email: Nawaid.Usmani@ahs.ca
- Phone: 780-432-8518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.